Revised Outcome of Board Meeting for Allotment of 1,30,90,200 Fully Convertible Equity Warrants on a preferential basis. Due to Technical Glitch the DSC on the Outcome is not visible. Hence ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mardia Samyoung Capillary Tubes Company Ltd has allotted 1,30,90,200 (about 1.31 crore) Fully Convertible Equity Warrants on a preferential basis to a single allottee, Torextron Ventures Private Limited, which belongs to the Promoter group. This is the second tranche of the preferential issue that was first approved by shareholders at an EGM on October 29, 2025 and received BSE in-principle approval on January 23, 2026. Each warrant is priced at Rs. 13.50 (face value Rs. 10 plus a premium of Rs. 3.50), taking the total warrant issue size to roughly Rs. 17.67 crore, of which 25% (around Rs. 4.42 crore) has already been received from the allottee as upfront payment. Each warrant can be converted into one equity share within 18 months, with the remaining 75% payable at the time of conversion. Because these are warrants and not shares, the company's paid-up share capital does not change at this stage.
The allotment involves only the Promoter group, so there is no change in control, but if all warrants are later converted into equity shares, the promoter's stake would marginally reduce from 23.51% to 21.99%, causing slight dilution. Existing retail shareholders should note potential future share supply when warrants convert, though near-term impact on share price is limited as no new equity is issued right now.